These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20034787)

  • 1. Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands.
    Ghosh AK; Gemma S; Simoni E; Baldridge A; Walters DE; Ide K; Tojo Y; Koh Y; Amano M; Mitsuya H
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1241-6. PubMed ID: 20034787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
    Ghosh AK; Kovela S; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
    J Med Chem; 2020 May; 63(9):4867-4879. PubMed ID: 32348139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.
    Ghosh AK; Yashchuk S; Mizuno A; Chakraborty N; Agniswamy J; Wang YF; Aoki M; Gomez PM; Amano M; Weber IT; Mitsuya H
    ChemMedChem; 2015 Jan; 10(1):107-15. PubMed ID: 25336073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors.
    Ghosh AK; Krishnan K; Walters DE; Cho W; Cho H; Koo Y; Trevino J; Holland L; Buthod J
    Bioorg Med Chem Lett; 1998 Apr; 8(8):979-82. PubMed ID: 9871524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.
    Ghosh AK; Martyr CD; Osswald HL; Sheri VR; Kassekert LA; Chen S; Agniswamy J; Wang YF; Hayashi H; Aoki M; Weber IT; Mitsuya H
    J Med Chem; 2015 Sep; 58(17):6994-7006. PubMed ID: 26306007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of potent HIV-1 protease inhibitors with (S)-tetrahydrofuran-tertiary amine-acetamide as P2-ligand: Structure-activity studies and biological evaluation.
    Bai X; Yang Z; Zhu M; Dong B; Zhou L; Zhang G; Wang J; Wang Y
    Eur J Med Chem; 2017 Sep; 137():30-44. PubMed ID: 28554091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
    Ghosh AK; Gemma S; Baldridge A; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
    J Med Chem; 2008 Oct; 51(19):6021-33. PubMed ID: 18783203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors.
    Ghosh AK; Chapsal BD; Baldridge A; Ide K; Koh Y; Mitsuya H
    Org Lett; 2008 Nov; 10(22):5135-8. PubMed ID: 18928291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.
    Baldwin ET; Bhat TN; Gulnik S; Liu B; Topol IA; Kiso Y; Mimoto T; Mitsuya H; Erickson JW
    Structure; 1995 Jun; 3(6):581-90. PubMed ID: 8590019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.
    Ghosh AK; Chapsal BD; Steffey M; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2308-11. PubMed ID: 22364812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.
    Ghosh AK; Chapsal BD; Baldridge A; Steffey MP; Walters DE; Koh Y; Amano M; Mitsuya H
    J Med Chem; 2011 Jan; 54(2):622-34. PubMed ID: 21194227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation.
    Ghosh AK; Williams JN; Kovela S; Takayama J; Simpson HM; Walters DE; Hattori SI; Aoki M; Mitsuya H
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2565-2570. PubMed ID: 31416666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.
    Le VD; Mak CC; Lin YC; Elder JH; Wong CH
    Bioorg Med Chem; 2001 May; 9(5):1185-95. PubMed ID: 11377177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
    Ghosh AK; Gemma S; Takayama J; Baldridge A; Leshchenko-Yashchuk S; Miller HB; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
    Org Biomol Chem; 2008 Oct; 6(20):3703-13. PubMed ID: 18843400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.
    Ghosh AK; Parham GL; Martyr CD; Nyalapatla PR; Osswald HL; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
    J Med Chem; 2013 Sep; 56(17):6792-802. PubMed ID: 23947685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
    Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
    J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of HIV protease inhibitors containing allophenylnorstatine as a transition-state mimic.
    Kiso Y
    Adv Exp Med Biol; 1995; 362():413-23. PubMed ID: 8540352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.